Stock Updates

How has Regeneron Pharmaceuticals, Inc.:(NASDAQ:REGN) performed recently?

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) is a large market cap stock with a market cap of 45009.47. It is in the Biotechnology industry and sector Healthcare, with a current P/E of 65.66, a forward P/E of 29.15 and EPS of 6.41. At a stock price of 422 (0.33%) it has a dividend yield of *TBA.

EPS growth for the last five years have been 44.90%, more recently this last year it has grown by 85.10%. The next year growth is going to be about 31.79% and more long-term 18.62% after five years. EPS growth quarter over quarter is 0.00%. Sales growth for the past five years have been 55.00% and sales growth quarter over quarter is 21.40%.

For performance, Regeneron Pharmaceuticals, Inc. the past week has seen a gain of 1.69%. For the last month performance for Regeneron Pharmaceuticals, Inc. is 6.51%. While the last quarter is 5.76% and half year, 6.85%. Finally for the year, performance is -16.64%.

The 52-week high for Regeneron Pharmaceuticals, Inc., is at -28.79%, and for the 52-week low it comes to a value of 28.23%. The 20-day simple moving average is 8.80% and -1.44% for the 200-day simple moving average.

Volatility for the week is at 2.14%, and for the month it is 2.51%. Regeneron Pharmaceuticals, Inc., has a target price of 466.64.

In terms of debt, long term debt/equity is 0.09, and for total debt/equity Regeneron Pharmaceuticals, Inc. has 0.09. The gross margin is 91.40%, while operating margin is 33.80%, the profit margin is 19.50%. The current ratio is 3.4 and the quick ratio is 3.1.

Insider ownership is at 0.50%, with instituitional ownership at 71.00%. Regeneron Pharmaceuticals, Inc. has a payout ratio of 0.00%. With the total shares outstanding coming to 107.01. The shares float is 77.55, with the float short at 4.68%, with short ratio coming to 4.35.

In terms of returns, the return on assets see Regeneron Pharmaceuticals, Inc., get 15.90%, with its returns on investment at 16.00%. Return on equity is 24.60%. So will the investors see the target price of 466.64, reached soon?

Disclaimer: Remember there is a risk to your investment, this is not a recommendation, nor personal advice, never invest more than you are able too loose.


About the author

Peter Clarke

Leave a Comment